Betapace Indication:

For the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (AFIB/AFL)] in patients with symptomatic AFIB/AFL who are currently in sinus rhythm. Also for the treatment of documented life-threatening ventricular arrhythmias.

Betapace Mechanism Of Action:

Betapace has both beta-adrenoreceptor blocking (Vaughan Williams Class I) and cardiac action potential duration prolongation (Vaughan Williams Class I) antiarrhythmic properties. Betapace is a racemic mixture of d- and l-sotalol. Both isomers have similar Class I antiarrhythmic effects, while the l-isomer is responsible for virtually all of the beta-blocking activity.

Betapace Drug Interactions:

Not Available

Betapace Food Interactions:

Not Available

Betapace Generic Name:

Synonyms:

  • Sotalol HCL

Drug Type:

Small Molecule; Approved

Absorption:

In healthy subjects, the oral bioavailability of sotalol is 90-100%. Absorption is reduced by approximately 20% compared to fasting when administered with a standard meal.

Toxicity (Overdose):

The most common signs to be expected are bradycardia, congestive heart failure, hypotension, bronchospasm and hypoglycemia. In cases of massive intentional overdosage (2-16 grams) of sotalol the following clinical findings were seen: hypotension, bradycardia, cardiac asystole, prolongation of QT interval, Torsade de Pointes, ventricular tachy-cardia, and premature ventricular complexes.

Protein Binding:

Sotalol does not bind to plasma proteins.

Biotransformation:

Sotalol is not metabolized.

Half Life:

Mean elimination half-life is 12 hours. Impaired renal function in geriatric patients can increase the terminal elimination half-life.

Dosage Forms of Betapace:

Tablet Oral

Chemical IUPAC Name:

N-[4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide

Organisms Affected:

Humans and other mammals

Betapace to general, pharmacology

General, pharmacology..